Reimagine Care的动态

You’re invited! On 25 April, Johnson & Johnson Innovation JLABS and Johnson & Johnson Innovative Medicine oncology teams in Europe will host a hybrid symposium titled “From concept to cure: Empowering start-ups in oncology innovation”. Briefly: navigating the development of new oncology solutions is a daunting challenge for startups, given the diverse nature of this selection of diseases, fierce competition in targets and approaches, and the stringent regulatory landscape. Incubation and strategic collaborations might prove valuable avenues to overcome these hurdles and carve a distinctive path in this competitive arena. These collaborations may provide access to specialized expertise and resources to fast-track their innovations.. Please follow the link to access additional details, the agenda, and to register. #mycompany

Roche is reportedly exploring options for its Flatiron Health unit, a leader in #cancer data specialization. All options are on the table, including #divesting the business or finding a strategic #partner to co-manage operations. In 2018, Roche made waves by #acquiring Flatiron Health for a staggering $1.9 billion. The company aimed to leverage Flatiron’s real-world evidence databank to enhance?#personalized?healthcare strategies in?#oncology. This move was hailed as one of the boldest in the industry, underlining Roche's commitment to innovation in #cancer treatment. However, the landscape has shifted significantly. Many of the Roche executives who championed the Flatiron #acquisition have since moved on, and the company has faced challenges reflected in its two-year period of share price decline. Stay informed. Stay ahead. Together, let's shape the future of healthcare. ?? https://lnkd.in/dxg7bkka

Cleveland Diagnostics, Inc. ???????? ?? ??????????????????, ???????????????? ???????? $?????? ???? ???????????? ?????????????? ??????????????????. ?? Led by global life sciences investor Novo Holdings, the funds will fast-track the commercialization of IsoPSA?, a ground-breaking blood test for stratifying prostate cancer risk. ???????????????empowers healthcare providers, aiding in informed biopsy decisions and minimizing overdiagnosis. ?? Arnon Chait, Ph.D., CEO & co-founder, expresses gratitude for investor confidence, highlighting the company's growth potential and financial discipline. ?? Anticipating increased test utilization, Cleveland Diagnostics, Inc. aims to achieve key clinical and regulatory milestones in 2024. ?? Beyond prostate cancer, the company envisions expanding applications, revolutionizing diagnostics for various cancers and diseases. ?? Elevating patient outcomes and quality of life remains a core focus. Exciting times ahead for Cleveland Diagnostics, Inc.! #HealthcareInnovation #FundingNews #MedicalAdvancements #ClevelandDiagnostics

???? Excited to share insights from Advisory Board Research on the evolution of value-based payment in oncology over the past decade. ?? ? Here are my three key takeaways: ? 1?? **Evolution of Approaches**: The value-based payment landscape in oncology has evolved significantly. From initial frameworks to nuanced models, the journey reflects a commitment to improving patient outcomes while controlling costs. ? 2?? **Systematic Challenges**: Despite progress, systematic challenges persist. Addressing issues such as data interoperability, standardization of quality measures, and aligning incentives across stakeholders is crucial for the widespread adoption of value-based payments in oncology. ? 3?? **Enabling Future Success**: Industry stakeholders play a pivotal role in enabling the future of value-based payment. Collaboration, innovation, and a patient-centric focus are essential to driving meaningful change and realizing the full potential of value-based care in oncology. ? Moreover, public sharing of experiences among industry stakeholders is vital. By learning from each other, preventing the repetition of mistakes, and collectively moving towards widely adopted models, we can accelerate progress in value-based payment adoption in oncology. ? Let's share best practices to drive the transformation of oncology care. ? #ValueBasedCare #Oncology #HealthcareInnovation #Collaboration #advisoryboard?

Should be timely, informative and fun.

???Exciting Collaboration Alert: OncoRevive Partners with Metrohm! I am delighted to announce an innovative partnership between OncoRevive and Metrohm, a global leader in high-precision instruments for chemical analysis. Metrohm's dedication to pioneering analytical solutions makes them an ideal partner as we strive to transform cancer diagnostics. Why Metrohm? Metrohm is renowned for its accuracy and reliability in the field of chemical analysis, characteristics that are critical as we develop advanced diagnostic tools. Their commitment to technological excellence supports our goal to set new standards in healthcare. Our Partnership: Through this partnership, OncoRevive will leverage Metrohm's expertise to enhance our cutting-edge liquid biopsy technology. This collaboration aims to dramatically improve diagnostic precision, speed, and comprehensiveness while reducing operational costs by 40%. These improvements are crucial for early cancer detection and better patient outcomes. Looking Ahead: Joining forces with Metrohm not only boosts our research capabilities but also sets the stage for significant advancements in cancer care. This partnership underscores our commitment to providing innovative solutions that can lead to life-saving diagnostics. We are thrilled about the potential impact of our collaboration and look forward to sharing more updates as we advance in our mission to revolutionize cancer diagnostics. #CancerResearch #InnovationInHealthcare #Partnership #OncoRevive #Metrohm #LiquidBiopsy #EarlyDetection

Great achievement for Scinvivo B.V., one of NLC Health Ventures' ventures. Congrats to Marijn van Os, Maaike de Jong and the whole Scinvivo team. And let's not forget . . .great news for patients around the world!! #earlystage #earlystageinvesting #impactinvesting #innovacion #healthtech #healthtechinnovation

??I haven't met anyone untouched, either directly or indirectly, by the impact of Cancer. ? As we reflected on World Cancer Day yesterday, our global community united to collectively voice our opposition to cancer. In the dynamic industries of biotechnology and pharmaceuticals, groundbreaking strides are being made in the fight against cancer. HOWEVER... ?? Biotech & Pharma firms pioneering oncology breakthroughs face significant fundraising hurdles. Investors display increased caution, and individuals are showing reluctance to join companies with a focus on oncology. INSTEAD... ?? FDA approvals for obesity and Alzheimer's treatments, including Eli Lilly and Company Zepbound and Eisai US and Biogen's Leqembi, are driving substantial funding to specialized companies. Notably, OrsoBio recently secured $60 million in a successful Series A funding round to advance their innovative programs focused on obesity and metabolic disorders. THEREFORE... ?? As we celebrate the strides made in oncology, it's crucial to recognize the financial hurdles these biotech's face. Individuals who remain therapeutically agnostic stand out in the dynamic and ever-changing industry. ?? Are you agnostic and seeking a fresh start in 2024? Let's jump on an introductory conversation! #worldcancerday #worldcancerawarenessday #biotechnology #pharmaceuticals #fundraising #venturecapital #diversity #therapeuticallyagnostic #2024goals

We're honored to have been featured in VentureBeat, Fierce Healthcare, Forbes, TechCrunch and many more outlets. The press coverage highlights how we: ?? Matched oncology patients and clinical trials with 95% accuracy alongside one of our collaborating cancer centers ?? Have onboarded half a dozen early partners, with plans to scale even further these next few months ? Help streamline not just patient-trial matching, but also quality reporting, quality improvement initiatives, precharting, clinical pathway workflows and more ???? Raised $15m to continue to raise the bar, including with the latest version of our OncoLLM that outperforms trained experts and GPT-4 alike. ?? Article links: https://lnkd.in/gAGR52rs - VentureBeat https://lnkd.in/gBwQ2GSJ - Fierce Healthcare https://lnkd.in/ggnbGHWG - Forbes https://lnkd.in/gjytiJkg - TechCrunch

Excited to check out the valuable insights at Cambridge VIP: Venture, Innovation & Partnering's Oncology Venture, Innovation & Partnering Summit tomorrow Oct 9-10 in Cambridge produced by Cambridge Innovation Institute!?Let me know if you are also attending and want to connect. #oncology #innovation #intellectualproperty #patentlaw #venture #diagnostics #therapeutics #cambridgema #strategy